267 related articles for article (PubMed ID: 32770028)
1. Mutant p53 induces Golgi tubulo-vesiculation driving a prometastatic secretome.
Capaci V; Bascetta L; Fantuz M; Beznoussenko GV; Sommaggio R; Cancila V; Bisso A; Campaner E; Mironov AA; Wiśniewski JR; Ulloa Severino L; Scaini D; Bossi F; Lees J; Alon N; Brunga L; Malkin D; Piazza S; Collavin L; Rosato A; Bicciato S; Tripodo C; Mantovani F; Del Sal G
Nat Commun; 2020 Aug; 11(1):3945. PubMed ID: 32770028
[TBL] [Abstract][Full Text] [Related]
2. A mutant p53/Hif1α/miR-30d axis reprograms the secretory pathway promoting the release of a prometastatic secretome.
Capaci V; Mantovani F; Sal GD
Cell Stress; 2020 Oct; 4(11):261-264. PubMed ID: 33150301
[No Abstract] [Full Text] [Related]
3. Functional studies of a novel germline p53 splicing mutation identified in a patient with Li-Fraumeni-like syndrome.
Piao J; Sakurai N; Iwamoto S; Nishioka J; Nakatani K; Komada Y; Mizutani S; Takagi M
Mol Carcinog; 2013 Oct; 52(10):770-6. PubMed ID: 22495821
[TBL] [Abstract][Full Text] [Related]
4. Mutant p53-R273H gains new function in sustained activation of EGFR signaling via suppressing miR-27a expression.
Wang W; Cheng B; Miao L; Mei Y; Wu M
Cell Death Dis; 2013 Apr; 4(4):e574. PubMed ID: 23559009
[TBL] [Abstract][Full Text] [Related]
5. The amplifier effect: how Pin1 empowers mutant p53.
Hu H; Wulf GM
Breast Cancer Res; 2011 Oct; 13(5):315. PubMed ID: 22017796
[TBL] [Abstract][Full Text] [Related]
6. Germ-line mutations of the p53 tumor suppressor gene in patients with high risk for cancer inactivate the p53 protein.
Frebourg T; Kassel J; Lam KT; Gryka MA; Barbier N; Andersen TI; Børresen AL; Friend SH
Proc Natl Acad Sci U S A; 1992 Jul; 89(14):6413-7. PubMed ID: 1631137
[TBL] [Abstract][Full Text] [Related]
7. p53's Extended Reach: The Mutant p53 Secretome.
Pavlakis E; Stiewe T
Biomolecules; 2020 Feb; 10(2):. PubMed ID: 32075247
[TBL] [Abstract][Full Text] [Related]
8. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome.
Lang GA; Iwakuma T; Suh YA; Liu G; Rao VA; Parant JM; Valentin-Vega YA; Terzian T; Caldwell LC; Strong LC; El-Naggar AK; Lozano G
Cell; 2004 Dec; 119(6):861-72. PubMed ID: 15607981
[TBL] [Abstract][Full Text] [Related]
9. A new therapeutic basis for treating Li-Fraumeni Syndrome breast tumors expressing mutated TP53.
Glazer RI
Oncotarget; 2010 Nov; 1(7):470-471. PubMed ID: 21317445
[No Abstract] [Full Text] [Related]
10. Mutant p53 induces a hypoxia transcriptional program in gastric and esophageal adenocarcinoma.
Sethi N; Kikuchi O; McFarland J; Zhang Y; Chung M; Kafker N; Islam M; Lampson B; Chakraborty A; Kaelin WG; Bass AJ
JCI Insight; 2019 Aug; 4(15):. PubMed ID: 31391338
[TBL] [Abstract][Full Text] [Related]
11. Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis.
Hanel W; Marchenko N; Xu S; Yu SX; Weng W; Moll U
Cell Death Differ; 2013 Jul; 20(7):898-909. PubMed ID: 23538418
[TBL] [Abstract][Full Text] [Related]
12. p53 loss activates prometastatic secretory vesicle biogenesis in the Golgi.
Tan X; Banerjee P; Shi L; Xiao GY; Rodriguez BL; Grzeskowiak CL; Liu X; Yu J; Gibbons DL; Russell WK; Creighton CJ; Kurie JM
Sci Adv; 2021 Jun; 7(25):. PubMed ID: 34144984
[TBL] [Abstract][Full Text] [Related]
13. p53 and disease: when the guardian angel fails.
Royds JA; Iacopetta B
Cell Death Differ; 2006 Jun; 13(6):1017-26. PubMed ID: 16557268
[TBL] [Abstract][Full Text] [Related]
14. A molecular signature of normal breast epithelial and stromal cells from Li-Fraumeni syndrome mutation carriers.
Herbert BS; Chanoux RA; Liu Y; Baenziger PH; Goswami CP; McClintick JN; Edenberg HJ; Pennington RE; Lipkin SM; Kopelovich L
Oncotarget; 2010 Oct; 1(6):405-422. PubMed ID: 21311097
[TBL] [Abstract][Full Text] [Related]
15. Detection of both mutant and wild-type p53 protein in normal skin fibroblasts and demonstration of a shared 'second hit' on p53 in diverse tumors from a cancer-prone family with Li-Fraumeni syndrome.
Srivastava S; Tong YA; Devadas K; Zou ZQ; Sykes VW; Chen Y; Blattner WA; Pirollo K; Chang EH
Oncogene; 1992 May; 7(5):987-91. PubMed ID: 1373881
[TBL] [Abstract][Full Text] [Related]
16. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM.
Song H; Hollstein M; Xu Y
Nat Cell Biol; 2007 May; 9(5):573-80. PubMed ID: 17417627
[TBL] [Abstract][Full Text] [Related]
17. Amino-terminal p53 mutations lead to expression of apoptosis proficient p47 and prognosticate better survival, but predispose to tumorigenesis.
Phang BH; Othman R; Bougeard G; Chia RH; Frebourg T; Tang CL; Cheah PY; Sabapathy K
Proc Natl Acad Sci U S A; 2015 Nov; 112(46):E6349-58. PubMed ID: 26578795
[TBL] [Abstract][Full Text] [Related]
18. Rescue of embryonic stem cells from cellular transformation by proteomic stabilization of mutant p53 and conversion into WT conformation.
Rivlin N; Katz S; Doody M; Sheffer M; Horesh S; Molchadsky A; Koifman G; Shetzer Y; Goldfinger N; Rotter V; Geiger T
Proc Natl Acad Sci U S A; 2014 May; 111(19):7006-11. PubMed ID: 24778235
[TBL] [Abstract][Full Text] [Related]
19. Exosomal microRNAs derived from colon cancer cells promote tumor progression by suppressing fibroblast TP53 expression.
Yoshii S; Hayashi Y; Iijima H; Inoue T; Kimura K; Sakatani A; Nagai K; Fujinaga T; Hiyama S; Kodama T; Shinzaki S; Tsujii Y; Watabe K; Takehara T
Cancer Sci; 2019 Aug; 110(8):2396-2407. PubMed ID: 31148360
[TBL] [Abstract][Full Text] [Related]
20. p53 signaling pathway polymorphisms, cancer risk and tumor phenotype in TP53 R337H mutation carriers.
Macedo GS; Vieira IA; Vianna FSL; Alemar B; Giacomazzi J; Brandalize APC; Caleffi M; Volc SM; de Campos Reis Galvão H; Palmero EI; Achatz MI; Ashton-Prolla P
Fam Cancer; 2018 Apr; 17(2):269-274. PubMed ID: 28756477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
